International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8229348
Original Article
Impact of Online Classes and Home Confinement on Prevalence of Myopia in Children during COVID-19 Pandemic
 ,
 ,
 ,
Published
Aug. 7, 2023
Abstract

Purpose: The aim of this study was to assess the prevalence of myopia in children before and after the Covid -19 pandemic.

Methods: This is a comprehensive retrospective study conducted in a secondary eye care centre at Panipat. All the children of the age group between 5-18 years were who attended our OPD were included. Period of study was April and May months of Year 2018, 2019, 2021, 2022. Visual acuity (unaided & aided) was recorded in all the children. The data was extracted, compared and analysed for difference in prevalence of myopia

Results: During the post Covid period (April-May 22), 710 children attended the OPD. Among these, 324 (47%) were having the refractive error of more than 0.5 D.  In comparison, in the same months of previous year 2021, only 349 children visited the OPD, out of these, 124 (38%) were having ref error. Secondly, in  the months of April May 2022, 128 children of the age group of 5-11 years got the refractive errors, out of 321 (39.9%) of the total children of the same age group who came to OPD during that period. In comparison, in the year 2021, only 25 (17%) got the refractive errors out of 147. This figure was much lower in the years 2018(6.3%) & 2019(6.8%).

Conclusion: After the COVID-19 pandemic, myopia showed an alarming increase in pediatric age group. The change of myopia in younger children was comparatively greater than that in adolescents. Therefore, measures should be taken to prevent and control the progression of myopia after the COVID-19 pandemic

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
1171 Views
179 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved